BCL2L1 and acute myeloid leukemia: Silencing of BAG1 in our AML model was shown to considerably reduce the expression of BCL2, a protein known to be an essential anti-apoptotic effector with important implications in drug resistance, but also of MCL1 and BCL-XL, whose involvement in AML has been well documented [38]–[40].